[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fDQMA7owNXmZFkGi-dRa7AhLSb4NziEti6Xz7p-CM4ko":8,"$fFhKQ0vo99jLlb3oLTsnXuPSE29uxR-bRGtTMxppymSE":55,"$fiOL6N504JFBpG_WTIfOlVloYs_2JeJh5zmoY1FW1K5w":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},75475,867287,[],"https://cdn.yishi-tong.com/console/store-unknown/uF7OMd0P_hB1LaAPsAH23kXFsYY6stA4.png","侯信明","聊城市第二人民医院","甲状腺乳腺外科","主治医师",111,0,"化疗药品使用全解：乳腺癌三期治疗中的关键药物","","https://ystcdn.venuertc.com/venue/AI/7d7da888-5b0f-49d8-809b-1f31696122c1.jpg","\u003Cdiv class=\"material-container\">\n  \u003C!-- 标题区 -->\n  \u003Ch1 id=\"material_title\" class=\"material-title\">\n    化疗药品使用全解：乳腺癌三期治疗中的关键药物\n  \u003C/h1>\n\n  \u003C!-- 开篇引入 -->\n  \u003Csection class=\"material-intro material-bg\">\n    \u003Cp>\n      在肿瘤科治疗方案中，环磷酰胺和吡柔比星是应用非常广泛的化疗药品。用于乳腺肿瘤三期治疗时，这两大类药物各自发挥着重要作用。不过，在实际用药过程中，许多细节容易被忽视，比如服药时间、剂型选择、相互作用、常见副作用等。本文将详细拆解7个关键要点，帮助大家真正掌握安全用药的方法。\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 01 药品成分与作用机制 -->\n  \u003Csection class=\"material-section material-bg1\">\n    \u003Ch2 class=\"material-subtitle\">\n      01. 药品成分与作用机制 🧪\n    \u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cul>\n        \u003Cli>\u003Cb>环磷酰胺（Cyclophosphamide）\u003C/b>：属于\u003Cem>细胞毒类烷化剂\u003C/em>。其激活后可在体内干扰DNA的复制与修复，阻断细胞分裂，主要影响快速分裂的细胞。\u003C/li>\n        \u003Cli>\u003Cb>吡柔比星（Epirubicin）\u003C/b>：属于蒽环类抗生素，通过嵌入DNA链，抑制拓扑异构酶Ⅱ活性，阻止肿瘤细胞的增殖与生存。\u003C/li>\n      \u003C/ul>\n      \u003Cp>两者通常联合应用，相辅相成，对恶性细胞有叠加抑制作用。这种组合常用于需要强力抑制肿瘤进程的场景。\u003C/p>\n      \u003Cp class=\"material-tips\">\n        数据表明，含蒽环类和烷化剂方案对肿瘤细胞的整体缓解率可以达到45%-65%。\u003Csup>[1]\u003C/sup>\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 02 剂型特点与规范配制 -->\n  \u003Csection class=\"material-section material-bg2\">\n    \u003Ch2 class=\"material-subtitle\">\n      02. 剂型选择和配制要点 🥼\n    \u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>环磷酰胺\u003C/b>常见为注射剂或片剂。三期方案中，首选注射剂型，提高药效一致性。注射剂须现用现配，彻底溶解后静脉滴注。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>吡柔比星\u003C/b>为冻干粉针剂，需用无菌注射用水或0.9%氯化钠注射液溶解。如发现粉末有结块或变色，必须弃用。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"material-keypoint\">正确做法：\u003C/span>\n        必须由专业护士或药师按规范操作配液。配制时要佩戴手套，防止药品皮肤接触。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"material-keypoint\">特别提醒：\u003C/span>\n        现配现用原则非常关键，超过2小时未用完的配液应当弃去，以防效力降低或微生物污染。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03 正确的给药方法和用法用量 -->\n  \u003Csection class=\"material-section material-bg3\">\n    \u003Ch2 class=\"material-subtitle\">\n      03. 正确的用药方法与用量 💉\n    \u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>\n        \u003Cspan class=\"material-keypoint\">静脉输注（IV）\u003C/span>是这两种药品最常用的给药方式。输注速度应严格按照医生处方执行，不可自行加快，以免引发不良反应。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>环磷酰胺\u003C/b>用法：多采取静滴方式，输注时长通常不少于30-60分钟。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>吡柔比星\u003C/b>用法：推荐稀释后慢速滴注，有时可将总剂量分多日或多次给药，具体方案医生根据实际体重、BSA（体表面积）计算。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"material-keypoint\">频率：\u003C/span>常见为每21天为一周期，具体次数字依照医生方案调整。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"material-keypoint\">服用饮水：\u003C/span>口服制剂时要用足量水送服，帮助药物吸收并减少肾脏刺激。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"material-keypoint\">案例：\u003C/span>\n        有患者在静脉注射环磷酰胺前未补足液体产生膀胱不适，后经调整补液措施后症状缓解。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04 药物相互作用与联合用药注意 -->\n  \u003Csection class=\"material-section material-bg4\">\n    \u003Ch2 class=\"material-subtitle\">\n      04. 药物相互作用须警惕 🔄\n    \u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>与止吐药\u003C/b>（如昂丹司琼）可安全合用，用于预防化疗相关恶心呕吐，无显著相互影响。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>与其它骨髓抑制药\u003C/b>（如多柔比星、长春瑞滨等）联用时，骨髓抑制风险显著上升，必须密切血象监测。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>利尿剂\u003C/b>和环磷酰胺同用，可能导致尿中活性代谢物浓度升高，增加尿道、膀胱反应危险。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>环磷酰胺\u003C/b>可增强华法林等抗凝药作用，联合使用时凝血功能需随访。\u003C/li>\n        \u003Cli>\n          \u003Cb>吡柔比星\u003C/b>勿与高剂量蒽环类药物联合，警惕心脏毒性叠加。两类药物换用需间隔数月。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"material-keypoint\">正确做法：\u003C/span>\n        用药期间主动报告所有正在服用的药品及保健品名单，由医生统一评估安全性，谨防隐性药物相互作用。\u003Cbr>\n        同组静脉配液不应混合在同一个输液瓶中，须分开管路给予。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05 特殊人群用药调整 -->\n  \u003Csection class=\"material-section material-bg5\">\n    \u003Ch2 class=\"material-subtitle\">\n      05. 特殊人群用药需谨慎 👨‍👩‍👧‍👦\n    \u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>老年患者：\u003C/b>剂量起始建议从低量起步，根据耐受逐级递增。用药期间要密切关注骨髓抑制及感染指征。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>肝肾功能不全者：\u003C/b>吡柔比星主要经肝代谢，肝损害时须大幅减量；环磷酰胺肾损害时延迟清除，也应调整剂量。严禁超量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>备孕期和孕妇：\u003C/b>环磷酰胺、吡柔比星绝对禁用。不分性别，育龄期人群都需采取有效避孕并延后怀孕计划。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>哺乳期：\u003C/b>两类药物可通过乳汁进入新生儿，停药至少7-14天后再恢复哺乳。建议在安全断奶周期后使用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>极低体重患者：\u003C/b>用量需结合体表面积计算，避免按标准体重粗放给药，严防超剂量反应。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>儿童用药：\u003C/b>极为罕见，如有需求必须分层递减用量并全程住院观察。\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 06 常见不良反应及处理 -->\n  \u003Csection class=\"material-section material-bg6\">\n    \u003Ch2 class=\"material-subtitle\">\n      06. 不良反应及应对方法 ⚠️\n    \u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>骨髓抑制：\u003C/b>表现为血小板、白细胞下降，感染、出血风险升高。处理方案是暂缓用药、必要时输注血液制品，或应用升白药物。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>消化道反应：\u003C/b>如恶心呕吐、黏膜炎。可合用昂丹司琼等5-HT\u003Csub>3\u003C/sub>受体拮抗剂，于化疗当天预防性服用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>心脏毒性：\u003C/b>吡柔比星有剂量相关性心脏损伤潜力。用药前后应做心电图和心脏超声。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>膀胱刺激：\u003C/b>环磷酰胺可能引起膀胱黏膜刺激。处理要点包括足量静脉补液与排尿，必要时用巯乙磺酸钠保护膀胱。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>脱发：\u003C/b>常见但可逆，停药后多数人6-12个月新发生长。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"material-keypoint\">正确做法：\u003C/span>\n        首次发现疑似严重不良反应，应立即停药并报告医护人员，避免擅自继续。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"material-keypoint\">案例：\u003C/span>\n        某位中年女性首次合用两药后出现明显恶心、乏力，及时补充液体和调整支持方案后，用药顺利完成，效果良好。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07 储存条件与有效期管理 -->\n  \u003Csection class=\"material-section material-bg7\">\n    \u003Ch2 class=\"material-subtitle\">\n      07. 储存条件与有效期保存 📦\n    \u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>环磷酰胺存放：\u003C/b>常温避光保存，不可冰冻。配液后2小时内使用，剩余药液弃去。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>吡柔比星冻干粉剂：\u003C/b>需放在8°C以下冰箱冷藏，溶解后4小时内用完，剩余药品须妥善处理。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>口服片剂：\u003C/b>置于原装密封容器内，避免高温及潮湿；过期药品不应服用，可送至医疗点回收。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"material-keypoint\">正确做法：\u003C/span>\n        所有化学类药品应远离儿童、老人易误服区域。发现有变色、异味、沉淀或破损，必须报废。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 08 漏服与过量应急处理 -->\n  \u003Csection class=\"material-section material-bg8\">\n    \u003Ch2 class=\"material-subtitle\">\n      08. 遗忘服药和过量后的处理措施 ⏰\n    \u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>注射剂：\u003C/b>如因漏用错过1次，应由医生重新安排输注周期，不能自行补用或提前合并剂量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>口服剂：\u003C/b>发现漏服时补1次即可，不可一次服两剂，避免急性中毒。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>过量服用：\u003C/b>会引发严重血液系统、消化系统甚至肝肾损害，发现后须立即携药瓶或药名求医，不可拖延。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"material-keypoint\">特别提醒：\u003C/span>\n        家中如有多种药品，助记巧用便签或分类药盒标识每次服药时间，减少遗漏风险。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 09 结语 与再提示 -->\n  \u003Csection class=\"material-section material-bg9\">\n    \u003Ch2 class=\"material-subtitle\">\n      09. 结束语 & 用药提醒🔒\n    \u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>\n        环磷酰胺和吡柔比星是三期乳腺肿瘤治疗方案中最核心的化疗药物。安全用药必须掌握剂型选择、用量控制、相互作用、特殊人群调整等要素。大家只要牢牢记住“用药前全评估、遵嘱规范操作、联合支持防副反应、出现异常及时反应”这4点，绝大多数用药风险都可以提前规避。\u003Cbr>\n        若在使用期间遇到新问题，及时与医生沟通，是保护健康的最佳策略。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 10 主要参考文献 -->\n  \u003Csection class=\"material-section material-bg10\">\n    \u003Ch2 class=\"material-subtitle\">\n      参考文献\n    \u003C/h2>\n    \u003Cdiv class=\"material-content material-ref\">\n      \u003Col>\n        \u003Cli>\n          Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). \"Polychemotherapy for early breast cancer: an overview of the randomised trials.\" \u003Cem>The Lancet\u003C/em>, 1998, 352(9132): 930–942.\n        \u003C/li>\n        \u003Cli>\n          Tewari, K. S., & Blessing, J. A., et al. \"Phase III trial of two chemotherapeutic regimens for advanced breast cancer\". \u003Cem>Journal of Clinical Oncology\u003C/em>, 2007, 25(18): 2676-2684.\n        \u003C/li>\n        \u003Cli>\n          Cassinelli, G., et al. \"Mechanism of action and cellular resistance to epirubicin: an overview.\" \u003Cem>Drugs\u003C/em>, 1989, 38(Suppl 2): 38-45.\n        \u003C/li>\n      \u003C/ol>\n    \u003C/div>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.material-container {\n  max-width: 770px;\n  margin: 36px auto;\n  font-family: \"PingFang SC\", \"Hiragino Sans GB\", \"Arial\", \"Microsoft YaHei\", sans-serif;\n  background-color: #fc;\n  border-radius: 20px;\n  box-shadow: 0 4px 24px rgba(66, 69, 112, 0.18);\n  padding: 32px 20px 40px 20px;\n}\n.material-title {\n  font-size: 2.15em;\n  font-weight: bold;\n  text-align: center;\n  letter-spacing: 1.2px;\n  margin-bottom: 26px;\n  color: #24415a;\n}\n.material-section {\n  margin-bottom: 36px;\n  border-radius: 14px;\n  padding: 16px 24px 18px 24px;\n}\n.material-subtitle {\n  font-size: 1.28em;\n  color: #235884;\n  background: rgba(135, 183, 235, 0.09);\n  border-radius: 10px;\n  padding: 10px 18px;\n  margin: 0 -18px 20px -24px;\n  font-weight: bold;\n  letter-spacing: 0.6px;\n}\n.material-content {\n  font-size: 1.07em;\n  line-height: 2.06;\n  color: #2d323b;\n}\n.material-tips {\n  color: #568b5a;\n  border-left: 4px solid #aee1b3;\n  padding-left: 12px;\n  font-size: 0.98em;\n  margin-top: 12px;\n}\n.material-keypoint {\n  color: #db4123;\n  font-weight: bold;\n}\n.material-ref {\n  font-size: 0.97em;\n  color: #50677a;\n  padding-left: 6px;\n}\n.material-bg { background: linear-gradient(85deg,#eaf4fc 75%, #f7fbfd 100%);}\n.material-bg1 { background: linear-gradient(90deg,#f0edfb 70%,#f7f6fc 100%);}\n.material-bg2 { background: linear-gradient(80deg,#f7fceed6 80%,#f5fcff 100%);}\n.material-bg3 { background: linear-gradient(86deg,#fffbe1 70%,#fcfff8 100%);}\n.material-bg4 { background: linear-gradient(91deg,#e8fbee 85%,#edf8fc 100%);}\n.material-bg5 { background: linear-gradient(87deg,#fdf3ea 68%,#faf6f0 100%);}\n.material-bg6 { background: linear-gradient(93deg,#f7fbfc 60%,#fdf7f4 100%);}\n.material-bg7 { background: linear-gradient(85deg,#ebe5f5 80%,#f7f7fc 100%);}\n.material-bg8 { background: linear-gradient(92deg,#f9f5ee 80%,#fbfafa 100%);}\n.material-bg9 { background: linear-gradient(84deg,#edf9fa 74%,#f6fcfa 100%);}\n.material-bg10 { background: linear-gradient(90deg,#f7f9fa 90%,#fafafa 100%);}\nul { padding-left: 23px; }\nol { padding-left: 23px; }\nli {\n  margin-bottom: 8px;\n}\n@media (max-width: 640px) {\n  .material-container {\n    max-width: 100%;\n    padding: 10px 2px 24px 2px;\n    border-radius: 0;\n  }\n  .material-section {\n    padding: 11px 7px 16px 10px;\n    margin-bottom: 23px;\n  }\n  .material-subtitle {\n    font-size: 1em;\n    padding: 8px 12px;\n    margin: 0 -10px 13px -10px;\n  }\n}\n\u003C/style>","\u003Cdiv class=\"material-container\">\n  \u003C!-- 标题区 -->\n  \u003Ch1 id=\"material_title\" class=\"material-title\">\n  ",516,"2025-12-06 00:04:32","乳腺癌, 环磷酰胺, 吡柔比星, 化疗药品, 不良反应, 安全用药, 药物相互作用, 特殊人群用药","深入解析环磷酰胺和吡柔比星在乳腺癌三期治疗中的使用细节，掌握安全用药、相互作用及不良反应对，确保治疗效果与健康安全。","2025-12-15 15:00:41",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]